Zacks Research Brokers Reduce Earnings Estimates for TSE:BHC

Bausch Health Companies Inc. (TSE:BHC) – Investment analysts at Zacks Research lowered their Q1 2025 EPS estimates for Bausch Health Companies in a note issued to investors on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the company will earn $1.16 per share for the quarter, down from their prior forecast of $1.25. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2025 earnings at $1.84 EPS, FY2025 earnings at $6.17 EPS, Q2 2026 earnings at $1.59 EPS and Q3 2026 earnings at $1.85 EPS.

Bausch Health Companies Price Performance

Bausch Health Companies stock opened at C$10.27 on Friday. The company has a 50-day moving average price of C$10.37 and a 200 day moving average price of C$10.61. Bausch Health Companies has a 12-month low of C$5.45 and a 12-month high of C$15.43. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of -1,831.94. The stock has a market cap of C$2.67 billion, a P/E ratio of -15.03, a PEG ratio of 0.21 and a beta of 0.77.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.